Previous Close | 2.9000 |
Open | 2.9000 |
Bid | 4.2000 |
Ask | 8.1000 |
Strike | 45.00 |
Expire Date | 2024-11-15 |
Day's Range | 2.9000 - 2.9000 |
Contract Range | N/A |
Volume | |
Open Interest | 10 |
Passive investing in index funds can generate returns that roughly match the overall market. But one can do better than...
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights Improvements in Fatigue and Exercise Capacity in Patients Treated with Mitapivat Compared to Placebo – – Agios to Webcast Virtual Investor Event on June 16, 2024 at 10 a.m. Eastern Time or 4 p.m. Central European Summer Time – CAMBRIDGE, Mass., June 15, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasd
Prestige Consumer Healthcare (PBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.